This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Watch These 3 MedTech Stocks This Earnings Season: Beat or Miss?
by Moumi Mondal
MedTech bigwigs, such as CVS, HOLX and IDXX, are set to post their quarterly results tomorrow. Can they deliver on expectations?
Waters (WAT) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Waters (WAT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Idexx Laboratories (IDXX) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Seeking Clues to Idexx (IDXX) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Idexx (IDXX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2025.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Idexx Laboratories (IDXX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Idexx (IDXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IDXX Gears Up for Q1 Earnings: What to Expect From the Stock?
by Zacks Equity Research
IDEXX Laboratories' first-quarter 2025 performance is expected to have benefited from a strong execution against strategic priorities.
IDEXX (IDXX) Surges 10.0%: Is This an Indication of Further Gains?
by Zacks Equity Research
IDEXX (IDXX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Here's Why Idexx Laboratories (IDXX) is a Strong Growth Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Will Idexx (IDXX) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Idexx (IDXX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Top Analyst Reports for Walt Disney, Progressive & Citigroup
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including The Walt Disney Co. (DIS), The Progressive Corp. (PGR) and Citigroup Inc. (C), as well as two micro-cap stocks Tucows Inc. (TCX) and Team, Inc. (TISI).
Should You Bet on PAHC Stock at a Discounted P/E of 10.41X?
by Moumi Mondal
PAHC's solid MFA franchise, now bolstered by Zoetis' portfolio, makes it a solid investment case. A well-established foothold in key regions is also a factor.
Should You Retain IDEXX Stock in Your Portfolio for Now?
by Zacks Equity Research
IDXX stays on investors' radar due to the strength of its CAG Diagnostics business.
Should Franklin U.S. Mid Cap Multifactor Index ETF (FLQM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FLQM
Idexx (IDXX) Down 5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should You Hold IDEXX Stock in Your Portfolio for Now?
by Zacks Equity Research
IDEXX's robust strength in the CAG Diagnostics business and strong global performance are highly promising.
Are Options Traders Betting on a Big Move in IDEXX (IDXX) Stock?
by Zacks Equity Research
Investors need to pay close attention to IDEXX (IDXX) stock based on the movements in the options market lately.
Company News for Feb 4, 2025
by Zacks Equity Research
Companies In The News Are: ARLP, TSN, IDXX, TWST.
Idexx (IDXX) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Idexx (IDXX) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
IDEXX Q4 Earnings and Revenues Top Estimates, Stock Up in Pre-Market
by Zacks Equity Research
IDXX delivers better-than-expected earnings and revenues in the fourth quarter of 2024.
Idexx Laboratories (IDXX) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Idexx (IDXX) delivered earnings and revenue surprises of 9.17% and 1.87%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
IDXX Gears Up for Q4 Earnings: What to Expect From the Stock?
by Zacks Equity Research
IDEXX Laboratories' fourth-quarter 2024 performance is expected to have benefited from a strong execution against strategic priorities.
IDXX Stock Set to Benefit From IDEXX Cancer Dx Diagnostic Panel Launch
by Zacks Equity Research
IDEXX launches new cancer Dx Panel with early detection test for canine lymphoma.